0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Drugs of UDCA - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-18T12212
Home | Market Reports | Health| Pharmacy
Global Drugs of UDCA Industry Research Report Growth Trends and Competitive Analysis 2022 2028
BUY CHAPTERS

Drugs of UDCA - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-18T12212
Report
September 2024
Pages:127
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Drugs of UDCA - Market Size

The global market for Drugs of UDCA was estimated to be worth US$ 1645 million in 2023 and is forecast to a readjusted size of US$ 3389.8 million by 2030 with a CAGR of 10.7% during the forecast period 2024-2030

Drugs of UDCA - Market

Drugs of UDCA - Market

The drug decreases the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients as an alternative to a surgical procedure to remove the gallstones.
UDCA is a bile acid used in the treatment of various liver disorders, such as primary biliary cholangitis and primary sclerosing cholangitis. The increasing prevalence of these liver diseases, along with growing awareness about their diagnosis and treatment, is driving market growth. Additionally, advancements in drug formulations, such as the development of extended-release and combination therapies, are further contributing to market expansion. The market is highly competitive, with several pharmaceutical companies actively engaged in the production and distribution of UDCA drugs. However, challenges such as high drug costs, side effects, and limited accessibility in certain regions may hinder market growth.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs of UDCA, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Drugs of UDCA by region & country, by Type, and by Application.
The Drugs of UDCA market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs of UDCA.
Market Segmentation

Scope of Drugs of UDCA - Market Report

Report Metric Details
Report Name Drugs of UDCA - Market
Forecasted market size in 2030 US$ 3389.8 million
CAGR 10.7%
Forecasted years 2024 - 2030
Segment by Type:
  • Capsule
  • Tablet
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini, Impax, Shanghai Pharma, Grindeks
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Drugs of UDCA manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Drugs of UDCA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Drugs of UDCA in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Drugs of UDCA - Market size in 2030?

Ans: The Drugs of UDCA - Market size in 2030 will be US$ 3389.8 million.

Who are the main players in the Drugs of UDCA - Market report?

Ans: The main players in the Drugs of UDCA - Market are Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini, Impax, Shanghai Pharma, Grindeks

What are the Application segmentation covered in the Drugs of UDCA - Market report?

Ans: The Applications covered in the Drugs of UDCA - Market report are Gallstone, Hepatopathy, Biliary Disease, Other

What are the Type segmentation covered in the Drugs of UDCA - Market report?

Ans: The Types covered in the Drugs of UDCA - Market report are Capsule, Tablet

Recommended Reports

Liver Disease Therapies

Bowel and Ulcer Drugs

Biliary and Cholesterol

1 Market Overview
1.1 Drugs of UDCA Product Introduction
1.2 Global Drugs of UDCA Market Size Forecast
1.2.1 Global Drugs of UDCA Sales Value (2019-2030)
1.2.2 Global Drugs of UDCA Sales Volume (2019-2030)
1.2.3 Global Drugs of UDCA Sales Price (2019-2030)
1.3 Drugs of UDCA Market Trends & Drivers
1.3.1 Drugs of UDCA Industry Trends
1.3.2 Drugs of UDCA Market Drivers & Opportunity
1.3.3 Drugs of UDCA Market Challenges
1.3.4 Drugs of UDCA Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Drugs of UDCA Players Revenue Ranking (2023)
2.2 Global Drugs of UDCA Revenue by Company (2019-2024)
2.3 Global Drugs of UDCA Players Sales Volume Ranking (2023)
2.4 Global Drugs of UDCA Sales Volume by Company Players (2019-2024)
2.5 Global Drugs of UDCA Average Price by Company (2019-2024)
2.6 Key Manufacturers Drugs of UDCA Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Drugs of UDCA Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Drugs of UDCA
2.9 Drugs of UDCA Market Competitive Analysis
2.9.1 Drugs of UDCA Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Drugs of UDCA Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs of UDCA as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Capsule
3.1.2 Tablet
3.2 Global Drugs of UDCA Sales Value by Type
3.2.1 Global Drugs of UDCA Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Drugs of UDCA Sales Value, by Type (2019-2030)
3.2.3 Global Drugs of UDCA Sales Value, by Type (%) (2019-2030)
3.3 Global Drugs of UDCA Sales Volume by Type
3.3.1 Global Drugs of UDCA Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Drugs of UDCA Sales Volume, by Type (2019-2030)
3.3.3 Global Drugs of UDCA Sales Volume, by Type (%) (2019-2030)
3.4 Global Drugs of UDCA Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Gallstone
4.1.2 Hepatopathy
4.1.3 Biliary Disease
4.1.4 Other
4.2 Global Drugs of UDCA Sales Value by Application
4.2.1 Global Drugs of UDCA Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Drugs of UDCA Sales Value, by Application (2019-2030)
4.2.3 Global Drugs of UDCA Sales Value, by Application (%) (2019-2030)
4.3 Global Drugs of UDCA Sales Volume by Application
4.3.1 Global Drugs of UDCA Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Drugs of UDCA Sales Volume, by Application (2019-2030)
4.3.3 Global Drugs of UDCA Sales Volume, by Application (%) (2019-2030)
4.4 Global Drugs of UDCA Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Drugs of UDCA Sales Value by Region
5.1.1 Global Drugs of UDCA Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Drugs of UDCA Sales Value by Region (2019-2024)
5.1.3 Global Drugs of UDCA Sales Value by Region (2025-2030)
5.1.4 Global Drugs of UDCA Sales Value by Region (%), (2019-2030)
5.2 Global Drugs of UDCA Sales Volume by Region
5.2.1 Global Drugs of UDCA Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Drugs of UDCA Sales Volume by Region (2019-2024)
5.2.3 Global Drugs of UDCA Sales Volume by Region (2025-2030)
5.2.4 Global Drugs of UDCA Sales Volume by Region (%), (2019-2030)
5.3 Global Drugs of UDCA Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Drugs of UDCA Sales Value, 2019-2030
5.4.2 North America Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Drugs of UDCA Sales Value, 2019-2030
5.5.2 Europe Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Drugs of UDCA Sales Value, 2019-2030
5.6.2 Asia Pacific Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Drugs of UDCA Sales Value, 2019-2030
5.7.2 South America Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Drugs of UDCA Sales Value, 2019-2030
5.8.2 Middle East & Africa Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Drugs of UDCA Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Drugs of UDCA Sales Value
6.2.1 Key Countries/Regions Drugs of UDCA Sales Value, 2019-2030
6.2.2 Key Countries/Regions Drugs of UDCA Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Drugs of UDCA Sales Value, 2019-2030
6.3.2 United States Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Drugs of UDCA Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Drugs of UDCA Sales Value, 2019-2030
6.4.2 Europe Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Drugs of UDCA Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Drugs of UDCA Sales Value, 2019-2030
6.5.2 China Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
6.5.3 China Drugs of UDCA Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Drugs of UDCA Sales Value, 2019-2030
6.6.2 Japan Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Drugs of UDCA Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Drugs of UDCA Sales Value, 2019-2030
6.7.2 South Korea Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Drugs of UDCA Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Drugs of UDCA Sales Value, 2019-2030
6.8.2 Southeast Asia Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Drugs of UDCA Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Drugs of UDCA Sales Value, 2019-2030
6.9.2 India Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
6.9.3 India Drugs of UDCA Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Dr. Falk Pharma
7.1.1 Dr. Falk Pharma Company Information
7.1.2 Dr. Falk Pharma Introduction and Business Overview
7.1.3 Dr. Falk Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Dr. Falk Pharma Drugs of UDCA Product Offerings
7.1.5 Dr. Falk Pharma Recent Development
7.2 Daewoong Pharmaceutical
7.2.1 Daewoong Pharmaceutical Company Information
7.2.2 Daewoong Pharmaceutical Introduction and Business Overview
7.2.3 Daewoong Pharmaceutical Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Daewoong Pharmaceutical Drugs of UDCA Product Offerings
7.2.5 Daewoong Pharmaceutical Recent Development
7.3 Teva
7.3.1 Teva Company Information
7.3.2 Teva Introduction and Business Overview
7.3.3 Teva Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Teva Drugs of UDCA Product Offerings
7.3.5 Teva Recent Development
7.4 Epic Pharma
7.4.1 Epic Pharma Company Information
7.4.2 Epic Pharma Introduction and Business Overview
7.4.3 Epic Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Epic Pharma Drugs of UDCA Product Offerings
7.4.5 Epic Pharma Recent Development
7.5 Mitsubishi Tanabe Pharma
7.5.1 Mitsubishi Tanabe Pharma Company Information
7.5.2 Mitsubishi Tanabe Pharma Introduction and Business Overview
7.5.3 Mitsubishi Tanabe Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Mitsubishi Tanabe Pharma Drugs of UDCA Product Offerings
7.5.5 Mitsubishi Tanabe Pharma Recent Development
7.6 Lannett
7.6.1 Lannett Company Information
7.6.2 Lannett Introduction and Business Overview
7.6.3 Lannett Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Lannett Drugs of UDCA Product Offerings
7.6.5 Lannett Recent Development
7.7 Mylan
7.7.1 Mylan Company Information
7.7.2 Mylan Introduction and Business Overview
7.7.3 Mylan Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Mylan Drugs of UDCA Product Offerings
7.7.5 Mylan Recent Development
7.8 Bruschettini
7.8.1 Bruschettini Company Information
7.8.2 Bruschettini Introduction and Business Overview
7.8.3 Bruschettini Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bruschettini Drugs of UDCA Product Offerings
7.8.5 Bruschettini Recent Development
7.9 Impax
7.9.1 Impax Company Information
7.9.2 Impax Introduction and Business Overview
7.9.3 Impax Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Impax Drugs of UDCA Product Offerings
7.9.5 Impax Recent Development
7.10 Shanghai Pharma
7.10.1 Shanghai Pharma Company Information
7.10.2 Shanghai Pharma Introduction and Business Overview
7.10.3 Shanghai Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Shanghai Pharma Drugs of UDCA Product Offerings
7.10.5 Shanghai Pharma Recent Development
7.11 Grindeks
7.11.1 Grindeks Company Information
7.11.2 Grindeks Introduction and Business Overview
7.11.3 Grindeks Drugs of UDCA Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Grindeks Drugs of UDCA Product Offerings
7.11.5 Grindeks Recent Development
8 Industry Chain Analysis
8.1 Drugs of UDCA Industrial Chain
8.2 Drugs of UDCA Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Drugs of UDCA Sales Model
8.5.2 Sales Channel
8.5.3 Drugs of UDCA Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Drugs of UDCA Market Trends
    Table 2. Drugs of UDCA Market Drivers & Opportunity
    Table 3. Drugs of UDCA Market Challenges
    Table 4. Drugs of UDCA Market Restraints
    Table 5. Global Drugs of UDCA Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Drugs of UDCA Revenue Market Share by Company (2019-2024)
    Table 7. Global Drugs of UDCA Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Drugs of UDCA Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Drugs of UDCA Price by Company (2019-2024) & (USD/Unit)
    Table 10. Key Manufacturers Drugs of UDCA Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Drugs of UDCA Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Drugs of UDCA
    Table 13. Global Drugs of UDCA Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs of UDCA as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Drugs of UDCA Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Drugs of UDCA Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Drugs of UDCA Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Drugs of UDCA Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Drugs of UDCA Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Drugs of UDCA Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Drugs of UDCA Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Drugs of UDCA Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Drugs of UDCA Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Drugs of UDCA Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Drugs of UDCA Price by Type (2019-2024) & (USD/Unit)
    Table 27. Global Drugs of UDCA Price by Type (2025-2030) & (USD/Unit)
    Table 28. Global Drugs of UDCA Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Drugs of UDCA Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Drugs of UDCA Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Drugs of UDCA Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Drugs of UDCA Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Drugs of UDCA Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Drugs of UDCA Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Drugs of UDCA Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Drugs of UDCA Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Drugs of UDCA Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Drugs of UDCA Price by Application (2019-2024) & (USD/Unit)
    Table 39. Global Drugs of UDCA Price by Application (2025-2030) & (USD/Unit)
    Table 40. Global Drugs of UDCA Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Drugs of UDCA Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Drugs of UDCA Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Drugs of UDCA Sales Value by Region (2019-2024) & (%)
    Table 44. Global Drugs of UDCA Sales Value by Region (2025-2030) & (%)
    Table 45. Global Drugs of UDCA Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Drugs of UDCA Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Drugs of UDCA Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Drugs of UDCA Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Drugs of UDCA Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Drugs of UDCA Average Price by Region (2019-2024) & (USD/Unit)
    Table 51. Global Drugs of UDCA Average Price by Region (2025-2030) & (USD/Unit)
    Table 52. Key Countries/Regions Drugs of UDCA Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Drugs of UDCA Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Drugs of UDCA Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Drugs of UDCA Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Drugs of UDCA Sales Volume, (2025-2030) & (K Units)
    Table 57. Dr. Falk Pharma Company Information
    Table 58. Dr. Falk Pharma Introduction and Business Overview
    Table 59. Dr. Falk Pharma Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 60. Dr. Falk Pharma Drugs of UDCA Product Offerings
    Table 61. Dr. Falk Pharma Recent Development
    Table 62. Daewoong Pharmaceutical Company Information
    Table 63. Daewoong Pharmaceutical Introduction and Business Overview
    Table 64. Daewoong Pharmaceutical Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 65. Daewoong Pharmaceutical Drugs of UDCA Product Offerings
    Table 66. Daewoong Pharmaceutical Recent Development
    Table 67. Teva Company Information
    Table 68. Teva Introduction and Business Overview
    Table 69. Teva Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 70. Teva Drugs of UDCA Product Offerings
    Table 71. Teva Recent Development
    Table 72. Epic Pharma Company Information
    Table 73. Epic Pharma Introduction and Business Overview
    Table 74. Epic Pharma Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 75. Epic Pharma Drugs of UDCA Product Offerings
    Table 76. Epic Pharma Recent Development
    Table 77. Mitsubishi Tanabe Pharma Company Information
    Table 78. Mitsubishi Tanabe Pharma Introduction and Business Overview
    Table 79. Mitsubishi Tanabe Pharma Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 80. Mitsubishi Tanabe Pharma Drugs of UDCA Product Offerings
    Table 81. Mitsubishi Tanabe Pharma Recent Development
    Table 82. Lannett Company Information
    Table 83. Lannett Introduction and Business Overview
    Table 84. Lannett Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 85. Lannett Drugs of UDCA Product Offerings
    Table 86. Lannett Recent Development
    Table 87. Mylan Company Information
    Table 88. Mylan Introduction and Business Overview
    Table 89. Mylan Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 90. Mylan Drugs of UDCA Product Offerings
    Table 91. Mylan Recent Development
    Table 92. Bruschettini Company Information
    Table 93. Bruschettini Introduction and Business Overview
    Table 94. Bruschettini Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 95. Bruschettini Drugs of UDCA Product Offerings
    Table 96. Bruschettini Recent Development
    Table 97. Impax Company Information
    Table 98. Impax Introduction and Business Overview
    Table 99. Impax Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 100. Impax Drugs of UDCA Product Offerings
    Table 101. Impax Recent Development
    Table 102. Shanghai Pharma Company Information
    Table 103. Shanghai Pharma Introduction and Business Overview
    Table 104. Shanghai Pharma Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 105. Shanghai Pharma Drugs of UDCA Product Offerings
    Table 106. Shanghai Pharma Recent Development
    Table 107. Grindeks Company Information
    Table 108. Grindeks Introduction and Business Overview
    Table 109. Grindeks Drugs of UDCA Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 110. Grindeks Drugs of UDCA Product Offerings
    Table 111. Grindeks Recent Development
    Table 112. Key Raw Materials Lists
    Table 113. Raw Materials Key Suppliers Lists
    Table 114. Drugs of UDCA Downstream Customers
    Table 115. Drugs of UDCA Distributors List
    Table 116. Research Programs/Design for This Report
    Table 117. Key Data Information from Secondary Sources
    Table 118. Key Data Information from Primary Sources
List of Figures
    Figure 1. Drugs of UDCA Product Picture
    Figure 2. Global Drugs of UDCA Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Drugs of UDCA Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Drugs of UDCA Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Drugs of UDCA Sales Price (2019-2030) & (USD/Unit)
    Figure 6. Drugs of UDCA Report Years Considered
    Figure 7. Global Drugs of UDCA Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Drugs of UDCA Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Drugs of UDCA Revenue in 2023
    Figure 10. Drugs of UDCA Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Capsule Picture
    Figure 12. Tablet Picture
    Figure 13. Global Drugs of UDCA Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Drugs of UDCA Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Global Drugs of UDCA Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 16. Global Drugs of UDCA Sales Volume Market Share by Type, 2023 & 2030
    Figure 17. Global Drugs of UDCA Price by Type (2019-2030) & (USD/Unit)
    Figure 18. Product Picture of Gallstone
    Figure 19. Product Picture of Hepatopathy
    Figure 20. Product Picture of Biliary Disease
    Figure 21. Product Picture of Other
    Figure 22. Global Drugs of UDCA Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global Drugs of UDCA Sales Value Market Share by Application, 2023 & 2030
    Figure 24. Global Drugs of UDCA Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 25. Global Drugs of UDCA Sales Volume Market Share by Application, 2023 & 2030
    Figure 26. Global Drugs of UDCA Price by Application (2019-2030) & (USD/Unit)
    Figure 27. North America Drugs of UDCA Sales Value (2019-2030) & (US$ Million)
    Figure 28. North America Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
    Figure 29. Europe Drugs of UDCA Sales Value (2019-2030) & (US$ Million)
    Figure 30. Europe Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
    Figure 31. Asia Pacific Drugs of UDCA Sales Value (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
    Figure 33. South America Drugs of UDCA Sales Value (2019-2030) & (US$ Million)
    Figure 34. South America Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
    Figure 35. Middle East & Africa Drugs of UDCA Sales Value (2019-2030) & (US$ Million)
    Figure 36. Middle East & Africa Drugs of UDCA Sales Value by Country (%), 2023 VS 2030
    Figure 37. Key Countries/Regions Drugs of UDCA Sales Value (%), (2019-2030)
    Figure 38. Key Countries/Regions Drugs of UDCA Sales Volume (%), (2019-2030)
    Figure 39. United States Drugs of UDCA Sales Value, (2019-2030) & (US$ Million)
    Figure 40. United States Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
    Figure 41. United States Drugs of UDCA Sales Value by Application (%), 2023 VS 2030
    Figure 42. Europe Drugs of UDCA Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Europe Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
    Figure 44. Europe Drugs of UDCA Sales Value by Application (%), 2023 VS 2030
    Figure 45. China Drugs of UDCA Sales Value, (2019-2030) & (US$ Million)
    Figure 46. China Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
    Figure 47. China Drugs of UDCA Sales Value by Application (%), 2023 VS 2030
    Figure 48. Japan Drugs of UDCA Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Japan Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
    Figure 50. Japan Drugs of UDCA Sales Value by Application (%), 2023 VS 2030
    Figure 51. South Korea Drugs of UDCA Sales Value, (2019-2030) & (US$ Million)
    Figure 52. South Korea Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
    Figure 53. South Korea Drugs of UDCA Sales Value by Application (%), 2023 VS 2030
    Figure 54. Southeast Asia Drugs of UDCA Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Southeast Asia Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
    Figure 56. Southeast Asia Drugs of UDCA Sales Value by Application (%), 2023 VS 2030
    Figure 57. India Drugs of UDCA Sales Value, (2019-2030) & (US$ Million)
    Figure 58. India Drugs of UDCA Sales Value by Type (%), 2023 VS 2030
    Figure 59. India Drugs of UDCA Sales Value by Application (%), 2023 VS 2030
    Figure 60. Drugs of UDCA Industrial Chain
    Figure 61. Drugs of UDCA Manufacturing Cost Structure
    Figure 62. Channels of Distribution (Direct Sales, and Distribution)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart